Research Information System
23rd European Congress of Endocrinology 2021, London, England, 22 - 26 May 2021, vol.73, pp.223-224, (Summary Text)
Aims/Introduction
We aimed to see whether Insulin Glargine U300 can provide better blood glucose control while reducing hypoglycemia in a more homogeneous population compared to previous studies.
Materials and methods
For evaluation of FBG, HbA1c and weight at 6 months and all variables final, observation windows of 120–240 days (4–8 months) and 240–480 days (9–16 months) after Insulin Glargine U300 initiation, respectively, were permitted. Hypoglycemia was defined as blood glucose level < 70 mg/dl, either symptomatic or asymptomatic, or measured in hospital or at home.
Results
The 35 patients comprised, 20 (57.1%) female and 15 (42.9%) men with a mean age of 24.1 ± 6.6 years. Mean BMI was 24.4 ± 7.4 kg/m2. Pre-study treatment regimens were given Table 1. A significant decrease was not found between baseline and HbA1C values in 6 month (P = 0.199) but in follow-up period (between 9–16 month) significant decrease was found (P = 0.025) (Table 2.). Hypoglycemic events occurred in all patients (100%) before using Insulin Glargine U300, while the incidence of hypoglycemic events gradually decreased to 74.3%, 68.6% and 68.6% between months 1–3, 3–6 and 6–9 respectively. Of the 26 patients that declared their satisfaction, 23 (88.5%) of them were satisfied, 2 (7.7%) of them indicated that there was no significant difference, and 1 (3.8%) patient was unsatisfied.
Conclusions
Over 9 – 16 month follow up period, Insulin Glargine U300 led to a significant reduction not only in HbA1c levels but also in the frequency of hypoglycemia, and also yielded high satisfaction rates.
Table 1. Pre-study treatment regimens
Treatment n (%)
Basal insulin + bolus insulin 35 (100)
IGlar U100 28 (80)
Insulin Detemir 7 (20)
Insulin Aspart 23 (65.7)
Insulin Lispro 8 (22.2)
Insulin Glulisin 4 (11.1)
Table 2. Comparison of baseline and final body weight, FBG, and HbA1C values
Means P**
Fasting blood glucose (mg/dl)†
Baseline – 6 month 191.2 ± 114.3–180.8 ± 97.9 0.678
Baseline – Final 191.2 ± 114.3–149.5.3 ± 62.4 0.043
6 month – Final 180.8 ± 97.9–149.5.3 ± 62.4 0.054
HbA1c (%)†[mmol/mol] †
Baseline – 6 month 9 ± 2[74.9 ± 21.9]–8.9 ± 2[73.8 ± 21.9] 0.199
Baseline – Final 9 ± 2[74.9 ± 21.9]–8.7 ± 1.6[71.6 ± 17.5] 0.025
6 month – Final 8.9 ± 2[73.8 ± 21.9]–8.7 ± 1.6[71.6 ± 17.5] 0.179
Weight (kg) †
Baseline – 6 month 66.3 ± 11.6–66.4 ± 12.1 0.835
Baseline – Final 66.3 ± 11.6–66.5 ± 12.8 0.796
6 month – Final 66.4 ± 12.1–66.5 ± 12.8 0.811
†: mean ± SD, **Paired t-test